drugset / Trial / NCT05320081
Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma
Phase 2
Unknown
30 enrolled
Huazhong University of Science and Technology
The First Affiliated Hospital of Nanchang University · collab
NaSingle-groupOpen-labelTreatment
Summary
The is a phase II, single-arm, open-label clinical study assessing the efficacy and safety of Camrelizumab combined with CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 30 subjects with r/r CD30+ lymphoma。
Timeline
- Start
- 2021-11-30
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD30.CAR-T | Cell therapy | 1e+07 cells/kg | — |
| Subject | Camrelizumab | Monoclonal antibody | — | — |